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Abstract
Bacteria that produce extended-spectrum b-lactamases (ESBLs) are an increasing healthcare problem and their rapid detection is a challenge
that must be overcome in order to optimize antimicrobial treatment and patient care. Matrix-assisted laser desorption ionization-time of
ﬂight (MALDI-TOF) mass spectrometry (MS) has been used to determine resistance to b-lactams, including carbapenems in
Enterobacteriaceae, but the methodology has not been fully validated as it remains time-consuming. We aimed to assess whether
MALDI-TOF can be used to detect ESBL-producing Enterobacteriaceae from positive blood culture bottles in clinical practice. In the assay,
141 blood cultures were tested, 13 of them were real bacteraemias and 128 corresponded to blood culture bottles seeded with bacterial
clinical isolates. Bacteraemias were analysed by MALDI-TOF after a positive growth result and the 128 remaining blood cultures 24 h after
the bacterial seeding. b-lactamase activity was determined through the proﬁle of peaks associated with the antibiotics cefotaxime and
ceftazidime and its hydrolyzed forms. Clavulanic acid was added to rule out the presence of non-ESBL mechanisms. Overall data show a 99%
(103 out of 104) sensitivity in detecting ESBL in positive blood cultures. Data were obtained in 90 min (maximum 150 min). The proposed
methodology has a great impact on the early detection of ESBL-producing Enterobacteriaceae from positive blood cultures, being a rapid and
efﬁcient method and allowing early administration of an appropriate antibiotic therapy.
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Introduction
Antibiotic resistance, which is currently one of the most
common healthcare problems worldwide [1,2], has increased
in recent years. This has created the challenge of ﬁnding new
methods to detect antibiotic-resistant bacteria as fast as
possible to enable appropriate antibiotic therapy to be
established.
In Gram-negative rods, especially Enterobacteriaceae, resis-
tance conferred by extended spectrum b-lactamases (ESBLs) is
the most prevalent type of b-lactam resistance and is
increasing worldwide [3]. Since the appearance of penicillin,
several forms of b-lactams have been described, including ﬁrst,
second, third, fourth and ﬁfth-generation cephalosporines,
b-lactam inhibitors, monobactams and carbapenemes [4,5].
Development of the therapeutic arsenal, coinciding with the
appearance of b-lactamases, has led to the need to develop
new susceptibility tests. More than 300 ESBLs have been
identiﬁed since the ﬁrst description of an ESBL, most of which
belong to the TEM, SHV and CTX-M families [6]. The latter is
the most prevalent worldwide, having replaced TEM and SHV
[7,8]. Mass spectrometry methods, such as MALDI-TOF,
detect mass shifts in the molecule we are following-up. To
detect bacteria having b-lactam enzymes by MALDI-TOF, the
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mass spectra of the antibiotic can be monitored, observing the
disappearance of the original mass peaks and the appearance of
new ones, corresponding to the hydrolyzed products as a new
structure is originated [9–11]. If bacteria are sensitive, the
antibiotic spectra will not change. Appearance of the mass
peak corresponding to the b-lactamase enzyme can be
monitored, but it has only been described for ampicillin-resis-
tant Escherichia coli [12] and for the identiﬁcation of CMY-2
b-lactamases [13]. Besides, these methods that focus on the
enzyme identiﬁcation are much slower and more tedious to
carry out in a clinical laboratory.
MALDI-TOF MS is routinely and satisfactorily applied to
identify bacteria in clinical microbiology laboratories. How-
ever, it has recently been used to detect microorganisms
harbouring speciﬁc antimicrobial resistance mechanisms [14].
The aim of this study was to assess whether MALDI-TOF
can be used in clinical practice to detect ESBL-producing
microorganisms from positive blood cultures.
Material and Methods
Bacterial strains
As a preliminary step and to optimize the methodology, we
built 10 isogenic E. coli strains expressing the following
b-lactamase (cephalosporinase) genes in the same
pBGS18-pCT vector (pB) (kanamycin resistance) and under
the control of a blaCTX-M promoter, being a multicopy
plasmid: blaTEM-1 (non-ESBL b-lactamase) as negative control,
blaSHV-12 (ESBL), blaTEM-29 (ESBL), blaCTX-M-32 (ESBL),
blaCTX-M-14 (ESBL), blaCTX-M-15 (ESBL), blaFOX-4 (AmpC-type),
blaCMY-2 (AmpC-type), blaDHA-1 (AmpC-type), blaDHA-6
(AmpC-type) and blaDHA-7 (AmpC-type) [15], with MICs
for both cefotaxime and ceftazidime antibiotics covering a
wide range (Table 1). Also, 128 bacterial clinical isolates
collected during 2012-2013 (seven wounds, one bile secre-
tion, one respiratory secretion and 119 ITU isolates) that
were seeded in blood culture bottles for further MALDI-TOF
analysis (only one strain by patient) were also included in this
study. These isolates were identiﬁed by MALDI-TOF mass
spectrometry (Bruker Daltonik GmbH, Bremen, Germany),
and antimicrobial susceptibility was determined by commer-
cial microdilution broth (Panel 53, Microscan walkaway
plus40, Siemens Erlanger, Germany) and the disk diffusion
test method. In several cases MICs were conﬁrmed by using
E-test strips (bioMerieux, Marcy l’Etoile, France). CLSI
criteria and EUCAST recommendations were followed
(www.eucast.org) for interpretation.
Among these 128 bacterial isolates, 22 were fully suscep-
tible to either CTX and CAZ (no ESBL or AmpC-type), 12 out
of 128 harboured AmpC-type enzymes and the remaining 94
isolates expressed ESBL b-lactamases, which were conﬁrmed
by phenotypic or molecular methods.
Thirteen positive blood cultures from patients with real
bacteraemia (2012–2013) were also included in the study (10
E. coli, seven harbouring ESBL and three fully susceptible to
third-generation cephalosporins, and three Klebsiella pneumo-
niae expressing an ESBL enzyme).
Preparation of fresh blood culture bottles and hydrolysis
assay
Prior to inoculation in blood culture bottles, 128 bacterial
clinical isolates were grown overnight on MacConkey-agar
plates at 37°C. For the 10 E. coli isogenic controls, LB-agar
TABLE 1. Cefotaxime and ceftazidime hydrolysis at the indicated time for the isogenic Escherichia coli control strains expressing
different b-lactamases.
Escherichia coli expressing the indicated b-lactamases
MIC (mg/L)
Hydrolysis time
60 min 90 min 120 min 180 min
CTX CAZ CTXa CAZb CTX CAZ CTX CAZ CTX CAZ
TEM-1 <1 1 c       
SHV-12 24 >256 +/d +/ +/ +e +/ + +/ +
TEM-29 <1 4      +/  +/
CTX-M-14 64 2 +  +  + +/ + +/
CTX-M-15 128 64 +  +  + + + +
CTX-M-32 >256 128 +  +  + +/ + +
FOX-4 >256 128 +  +  + +/ + +
CMY-2 4 48     +/ +/ + +
DHA-1 8 32     +/ +/ +/ +
DHA-6 1 4     +/ +/ +/ +/
DHA-7 32 128 +/ +/ + +/ + +/ + +
aCefotaxime.
bCeftazidime.
cThere is no hydrolysis observed.
dPartial antibiotic hydrolysis is detected. In the same spectrum both peaks from the non-hydrolyzed antibiotic and its hydrolyzed form are observed.
eTotal antibiotic hydrolysis.
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plates with kanamycin (50 mg/L) were added to maintain
antimicrobial pressure.
After an overnight incubation, the above-cited bacterial
isolates were seeded in blood culture bottles (BacT Alert,
Biomerieux; Durham). We inoculated 1 mL of a 0.5 McFarland
standard into blood culture bottles, which were incubated
overnight at 37°C.
Positive blood cultures from bacteraemic patients were
analyzed by MALDI-TOF after positivity was detected by the
BacT/Alert 3D system (Biomerieux).
Then, 1 mL of the blood culture was removed with a
syringe and proceeded to the protein extraction using the
MALDI Sepsityper Kit (Bruker Daltonik GmbH), following the
manufacturer’s instructions, except that the washing solution
was used twice instead of once in the last step [11]. The
bacterial pellet was resuspended in 50 lL of lysozyme (Sigma
Aldrich Munich, Germany, 40 mg/mL, in 50 mM tris-HCl
buffer and 10 mM EDTA pH = 8.0; Roche, Basel, Switzerland,
High Pure Plasmid Isolation Kit) and suspensions incubated at
37°C under agitation for 30 min [16]. Then, it was centrifuged
for 5 min at 8500 g and the supernatant processed with 10 lL
of cefotaxime (Sigma Aldrich; 500 mg/L) and/or ceftazidime
(Sigma Aldrich; 25 mg/L) and 10 lL of cefotaxime/ceftazidime
plus clavulanic acid (Sigma Aldrich; 50 mg/mL), for 60 and
120 min at 37°C, time that was optimized with control strains.
Cefotaxime was the ﬁrst antibiotic to be tested as CTX-M
enzymes are the most prevalent in our area and the expected
time of hydrolysis is shorter. Afterwards, ceftazidime was
tested. To conﬁrm the presence of an ESBL, we performed MS
peaks analysis in the presence or absence of clavulanic acid at
the above-indicated concentration.
MALDI-TOF MS analysis and calibration
We spotted 1 mL of the solution onto the MALDI target plate.
Once the spot dried (at room temperature), we placed 1 lL of
MALDI matrix (10 mg/mL of a-cyano-4-hydroxy-cinnamic acid
[a-HCCA] in 2.5% Triﬂuoroacetic-50% Acetonitrile, Bruker
Daltonik) on top of the spot. Once the matrix had dried, we
used ﬂexControl 3.0 software (Bruker Daltonik GmbH) with a
Microﬂex LT mass spectrometer to analyse the obtained
measures. The spectrometer was equipped with a 60.0 Hz
nitrogen laser, and the parameters were set as follows: Ion
Source 1, 18.99 KV; Ion Source 2, 16.29 KV; lens, 6.00 KV; and
low range mode. The mass range was between 100 and
1000 Da. Spectra were measured automatically. For calibra-
tion, we measured an external standard consisting of
573.31 Da bradykinin (1–5) (Sigma-Aldrich) and 757.40 Da
bradykinin (1–7) (Sigma-Aldrich) in the same way as the
samples. We also used peaks from the matrix, HCCA, for
calibration: [M+H]+ at 190.05 Da and [2M+H]+ at 379.02 Da.
Spectrum analysis
Selected mass peaks are as follow: cefotaxime [456.5,
396.5 Da] and ceftazidime [547.5, 468.5 Da] and for their
hydrolized products [414.5, 370.5 Da] and [486.5, 442.5 Da],
respectively [11]. We used Flexanalysis 3.3 software (Bruker
Daltonik GmbH) to analyse the spectra, which were smoothed
and baseline subtracted. Peaks were selected using the Snap
detection algorithm, a signal to noise threshold of 6, a relative
intensity threshold of 0%, a minimum intensity threshold of 0%,
a width peak of 0.75 m/z and Tophat baseline subtraction.
Characterization of b-lactamase genes
In some cases and to conﬁrm the b-lactam resistance
mechanism inferred by the phenotypic assay, some clinical
bacterial isolates were further characterized to identify the
b-lactamase gene involved in the antimicrobial resistance.
With this aim, PCR was used with b-lactamase’s known
oligonucleotides (Table 2) [17,18]. Clinical bacterial isolates
were randomly selected for the molecular study as follow: (i)
strains with cefotaxime MIC >32 mg/L (n = 10); (ii) strains
with cefotaxime MIC between 1.5 and 12 mg/L (n = 7) and (iii)
remaining strains with cefotaxime MIC <1 mg/L (n = 13). Also,
those bacterial isolates directly obtained from positive cultures
from bacteraemias were as well characterized: three sensitive
E. coli showing no phenotypic resistance, seven E. coli and
three K. pneumoniae with cefotaxime MIC >32 mg/L.
Results
Optimization of ESBL detection time
To optimize the detection time for the antibiotic hydrolysis,
supernatants from the isogenic E. coli strains harbouring
known b-lactamase genes were incubated with cefotaxime
and ceftazidime for different times: 30 min, 60 min, 90 min,
120 min and 180 min. On analysing the spectra (Fig. 1)
(Table 1), we found that CTX-M enzymes were capable of
hydrolyzing cefotaxime in 60 min, and as they are the most
prevalent ESBL in our area, this time was the chosen one for
TABLE 2. Primers used in this study
Target Primers Sequence (50 to 30)
CTX-M-
group 1
CTXM1F ATG GTG ACA AAG AGA ATG C
CTXM1R CAT CGC CGA AGG GTC GTA A
CTX-M-
group 9
CTXM9F ATG GTT AAA AAA TCA CTG CGT CAG TT
CTXM9R ATC GTC ACC AAC GGT TTG TAA
TEM-type TEM1B TGCTGAAGATCAGTTGG
TEM2B TAATTGTTGCCGGGAAAG
SHV-type SHV1A CCGGATCCATGCGTTATATTCGCCTGTG
SHV1B CCGGATCCTTAGCGTTGCCAGTGCTCG
CMY-2 CITMF TGG CCA GAA CTG ACA GGC AAA
CITMR TTT CTC CTG AAC GTG GTC GGC
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further studies with clinical isolates. We cannot guarantee a
sensitivity of 100% but shorten the response time of the
technique. Also, ceftazidime was tested as a second marker
for ESBL identiﬁcation. Time of exposure chosen for ceftaz-
idime hydrolysis detection by MALDI-TOF was 120 min,
which matches CMY-2 enzyme hydrolysis, as it is the most
prevalent AmpC-type enzyme in our area. At that time,
despite full ceftazidime hydrolysis is not being detected, the
mass hydrolysis peaks appearance suggests the presence of
b-lactamase activity and enables us to shorten the response
time.
The rest of the isogenic E. coli control trains expressing
different b-lactamases showed different hydrolysis times
depending on their respective antibiotic MICs (Table 1) and
they are shown as positive controls for exclusively compar-
ative purposes (Fig. 2).
379.190
445.135335.202 370.163 414.119
428.250
B
0.0
0.2
0.4
0.6
0.8
1.0
x104
x104
Intens. [a.u.]
379.152
445.094414.093
370.137335.181
441.351401.169 423.144
A
0
1000
2000
3000
4000
5000
6000
Intens. [a.u.]
a
379.190
445.135335.202
370.163
414.119
428.250
D
0.0
0.2
0.4
0.6
0.8
1.0
In
te
ns
. [
a.
u.
]
378.746
444.602
460.560
334.807 413.649400.713 422.649369.739 440.868
C
0
2000
4000
6000
8000
Intens. [a.u.]
476.868
467.937
460.908
547.035
E
0
500
1000
1500
2000
Intens. [a.u.] b 444.750
467.739
460.722
546.919
F
0
0
500
500
1000
1500
2000
Intens. [a.u.]
m/z
m/z
m/z
441.950
476.810
467.895
G
750
250
500
1000
1250
1500
Intens. [a.u.] 441.820 460.734
485.702
1000
1500
Intens. [a.u.]
H
m/z
m/z
m/zm/z
m/z m/z
(a)
FIG. 1. (a) Mass spectra of cefotaxime at 60 min (A), 90 min (B), 120 min (C) and 180 min (D) and ceftazidime at 60 min (E), 90 min (F), 120 min
(G) and 180 min (H) after exposure to the bacterial lysate of one isogenic Escherichia coli control strain expressing blaCTX-M-32. (1b) Mass spectra of
cefotaxime at 60 min (A), 90 min (B), 120 min (C) and 180 min (D) and ceftazidime at 60 min (E), 90 min (F), 120 min (G) and 180 min (H) after
exposure to the bacterial lysate of one isogenic E. coli control strain expressing blaCMY-2.
a Indicates the hydrolized peaks of the antibiotic. b?
Indicates the antibiotic mass peaks (no hydrolyzed form).
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MALDI-TOF MS assays with bacterial isolates from positive
blood culture bottles
The above-described conditions were used in the assay
validation, both with positive blood cultures from real
bacteraemias (n = 13) and with seeded blood culture bottles
with clinical bacterial isolates (n = 128).
Real bacteraemias corresponded to 13 positive blood
cultures: (i) three E. coli isolates fully susceptible to
cefotaxime and ceftazidime without any antibiotic resistance
mechanism; (ii) seven E. coli isolates showing high levels of
resistance (>32 mg/L) to cefotaxime and ceftazidime
(blaCTX-M-32) and (iii) three K. pneumoniae (>32 mg/L) also
showing high levels of resistance to CTX and CAZ
(blaCTX-M-15). When they were analysed by MALDI-TOF all
resistance bacterial isolates were correctly assigned as
ESBL producers, whereas no hydrolysis peaks were
detected in the susceptible isolates (Table 3). Overall data
showed 100% sensitivity and speciﬁcity of MALDI-TOF to
detect ESBL in positive blood cultures of bacteraemic
patients.
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FIG. 1. (continued)
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In order to increase the statistical signiﬁcance of our
ﬁndings, 128 bacterial clinical strains showing different levels of
resistance to CTX and CAZ were also used to blindly
inoculate blood cultures as described above. Then MALDI--
TOF analysis was performed and data analysed.
Among all bacterial isolates studied, MALDI-TOF identiﬁed
all ESBL producers except one E. coli (blaCTX-M-14,
MICCTX = 12 mg/L, MICCAZ ≤1 mg/L). Indeed, spectrophoto-
metric analysis just detected very weak cefotaxime hydrolysis
with this strain (data not shown). Among AmpC strains, six
E. coli (blaCMY-2, MICCTX from 1.5 to 8 mg/L) did not show
cefotaxime hydrolysis. However, we were able to detect CAZ
hydrolysis in four of them (MICCAZ >8 mg/L) (Table 4). The
remaining two blaCMY-2 isolates were undetectable by MAL-
DI-TOF (MICCAZ = 4 mg/L).
Results from MS hydrolysis in all bacterial isolates studied
correlated well with the resistance levels to cefotaxime and
ceftazidime. As MIC increased, the degree of antibiotic
hydrolysis identiﬁed by MS analysis was higher. Data revealed
that peaks resulting from cefotaxime or ceftazidime hydrolysis
disappeared when clavulanic acid was added in the case of an
ESBL mechanism, so the original mass peaks were restored. In
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FIG. 2. (a) Mass spectra of cefotaxime (A), cefotaxime plus clavulanic acid (B), ceftazidime (C) and ceftazidime plus clavulanic acid (D) after
exposure to the bacterial lysate at the time when the hydrolysis is higher. b-lactamase-type and time studied is indicated in the top right corner.
b-lactamases belong to control strains are as follows: TEM-1 (non-ESBL), SHV-12 (ESBL), TEM-29 (ESBL with higher activity toward ceftazidime),
CTX-M-14, -15, and -32 (ESBL), FOX-4, CMY-2, DHA-1, -6 and -7 (plasmidic AmpC-type enzymes) a Indicates the hydrolized peaks of the
antibiotic. b?Indicates the antibiotic mass peaks (no hydrolyzed form).
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contrast, all strains expressing AmpC-type b-lactamases
revealed unchanged peaks when the inhibitor was added. That
conﬁrmed the usefulness of adding clavulanic acid to detect an
ESBL mechanism.
In conclusion, MS analysis was useful for detecting the
presence of ESBL in clinical strains of Enterobacteriaceae
obtained from blood cultures. Results obtained by MALDI--
TOF match those obtained with control and clinical isolates
with ESBL conﬁrmed by either phenotypical or genotypical
methods. Data revealed that the assay has an overall sensitivity
of 99% (103/104) and speciﬁcity of 100% (104/104) in
predicting ESBL resistance mechanisms in clinical strains of
Enterobacteriaceae obtained from blood cultures. AmpC-pro-
ducers have a sensitivity of 83% (10/12) and a speciﬁcity of
100% (12/12). Nonetheless, a higher number of isolates
producing AmpC enzymes should be included in this study
to reach better conclusions.
Discussion
MALDI-TOF mass spectrometry has been used satisfactorily in
clinical microbiology laboratories for identiﬁcation of bacteria
[14]. However, MALDI-TOF analysis has recently been used to
infer the presence of speciﬁc antimicrobial resistance mech-
anisms [9–11,16,19,20]. Here we report a novel approach that
enables categorization of bacteria as ESBL producers according
to MS cefotaxime/ceftazidime peaks identiﬁed directly from
TABLE 3. Summary data of MALDI-TOF analysis of 13 positive blood culture bottles belonging to 13 different patients with
bacteraemia
CTX MIC (mg/L) (n)a CAZ MIC (mg/L) (n)a Bacterial species CTX MS positive resultb CAZ MS positive resultb Resistance mechanism
<=1 (n = 3) <=1 (n = 3) Escherichia coli (n = 3) 0% (0/3) 0% (0/3) None
>32 (n = 10) >32 (n = 10) E. coli (n = 7) 100% (7/7) 100% (7/7) bla CTX-M-32
Klebsiella pneumoniae (n = 3) 100% (3/3) 100% (3/3) bla CTX-M-15
aNumber of tested isolates at each MIC within parentheses.
bMS was considered positive when peaks of CTX and CAZ hydrolysis products were detected.
TABLE 4. Summary data of MALDI-TOF analysis of 128 seeded blood culture bottles with corresponding bacterial isolates
stratiﬁed by their MIC.
CTX MIC
(mg/L) (n)a
CAZ MIC
(mg/L) (n)a
Bacterial
species (n)a
CTX MS positive
resultb
CAZ MS positive
resultb
Resistance result by MS
(ESBL and/or AmpC)c
Resistance conﬁrmed
mechanism
<=1 (22) <=1 (22) Escherichia coli (1) 0% 0%  OXA-1
E. coli (8) 0% 0%  TEM-1d
Klebsiella pneumoniae (1) 0% 0%  SHV-1d
K. pneumoniae (4) 0% 0%  TEM-1 + SHV-1d
E. coli (8) 0% 0%  Noneg
1.5 (1) <1 (1) E. coli (1) 100% (1/1) 0% + AmpC (CMY-2)e
1.5 (1) ≥16 (1) E. coli (1) 0% (0/1) 100% (1/1) + AmpC (CMY-2)e
2 (1) <1(1) E. coli (1) 100% (1/1) 0% (0/1) + ESBL
2 (1) 16 (1) E. coli (1) 100% (1/1) 100% (1/1) + AmpC (CMY-2)e
2(2) 4 (2) E. coli (2) 0% (0/2) 0% (0/2)  AmpC (CMY-2)e
4 (1) 8 (1) E. coli (1) 0% (0/1) 100% (1/1) + AmpC (CMY-2)e
4 (1) 16 (1) E. coli (1) 0% (0/1) 100% (1/1) + AmpC (CMY-2)e
4 (2) 16 (2) K. pneumoniae (2) 100% (2/2) 100% (2/2) + ESBL
6 (1) 2 (1) K. pneumoniae (1) 100% (1/1) 0% (0/1) + ESBL
8 (1) 16 (1) E. coli (1) 100% (1/1) 100% (1) + ESBL
8 (1) ≥16 (1) E. coli (1) 0% (0/1) 100% (1/1) + AmpC (CMY-2)e
8 (1) ≥16 (1) K. pneumoniae (1) 100% (1/1) 100% + ESBL
12 (1) <=1 (1) E. coli (1) 0% (0/1/) 0%  ESBL (CTX-M-14)e
16 (1) 4 (1) E. coli (1) 100% (1/1) 0% (0/1) + ESBL
16 (2) 16 (2) E. coli (2) 100% (2/2) 100% (2/2) + ESBL
16 (1) 2 (1) Klebsiella oxytoca (1) 100% (1/1) 0% (0/1) + ESBL
16 (1) 4 (1) K. pneumoniae (1) 100% (1/1) 0% (0/1) + ESBL
16 (1) ≥16 (1) E. coli (1) 100% (1/1) 100% (1/1) + AmpC
>=32 (85) ≥16 (85) E. coli (3)
E. coli (73)
K. pneumoniae (9)
100% (85/85) 100% (85/85) + AmpC
ESBLf
ESBL
aThe total number of strains studied was 128, distributed as shown in the column.
bNumber of strains that yielded either cefotaxime or ceftazidime hydrolysis peaks among total strains studied at the indicated cefotaxime/ceftazidime MIC. All extracts from
bacterial isolates showed inhibition of cefotaxime/ceftazidime hydrolysis in the presence of clavulanic acid except those E. coli harbouring AmpC phenotypes.
cSuggested mechanism: ESBL and/or AmpC-type present (+), absent ().
dClinical isolates characterized by PCR.
eThe ampC-type gene was characterized as blaCMY-2 in six clinical isolates with MIC between 1.5–8 mg/L. One strain with the ESBL phenotype and MIC = 12 mg/L for cefotaxime
corresponded to a CTX-M-14 enzyme.
fESBL characterization of 10 randomly selected clinical isolates with cefotaxime MIC higher than 32 mg/L. Nine out of ten corresponded to a CTX-M-32 enzyme and the remaining
one corresponded to a CTX-M-14 enzyme.
gNo resistance mechanism was found in these strains.
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positive blood cultures. The overall expected time is <2 h,
taking into account protein extraction (5 min), hydrolysis assay
(90 min, maximum 120) and spectrum acquisition and analysis
(15 min). The assay is much faster than the methods used
routinely in clinical practice, which require the growth of
bacteria for at least 18–24 h.
The assay was validated with 141 bacterial isolates (13 real
bacteraemias), obtained from different patients, with different
types of b-lactamases and different levels of expression/
resistance. A qualitative relationship between MIC and the
degree of antibiotic hydrolysis obtained has been identiﬁed.
Detection of the antibiotic hydrolysis became faster as the
antibiotic MIC increased. Addition of clavulanic acid to the
kinetic assays was also very important as it allowed us to
associate antibiotic hydrolysis with a speciﬁc antimicrobial
resistance mechanism, such as the presence or absence of ESBL.
Recently, Sophia Jung et al. [20] obtained similar results in the
detection of b-lactam resistance in blood culture bottles using
ampicillin and cefotaxime; nevertheless, we have taken a step
forward in trying to obtain the resistance mechanism implied
and using a second cephalosporine because we were not able to
detect all cases of ESBL (sensitivity was lower than 100%) when
cefotaxime was used alone. The use of ceftazidime would
undoubtedly enable detection of those strains carrying ESBL
with a lower rate of cefotaxime hydrolysis but an increased
effect of ceftazidime or those AmpC-type b-lactamases that
have higher catalytic efﬁciency for ceftazidime than cefotaxime.
The sensitivity of ESBL detection is not really improved by
ceftazidime addition, as most of this phenotype is represented
by CTX-M-type enzymes, but the overall sensitivity of the assay
is increased and it is helpful for detecting AmpC strains, in our
case blaCMY-2. For the three strains (2 blaCMY-2 and 1
blaCTX-M-14) in which the assay result was negative either for
cefotaxime or ceftazidime hydrolysis, we conﬁrmed it by
spectrophotometry as the reference method. No hydrolysis
at all was observed for both blaCMY-2 strains for both antibiotics
(MICCTX = 2 mg/L, MICCAZ = 4 mg/L). The strain carrying
blaCTX-M-14 (MICCTX = 12 mg/L, MICCAZ ≤1 mg/L) has a very
weak hydrolysis for cefotaxime and no hydrolysis at all for
ceftazidime.
This MALDI-TOF mass spectrometry assay for detecting
ESBL in positive blood cultures is 99% sensitive and 100%
speciﬁc. Hence, it is a very useful assay for clinicians searching
for the most appropriate antibiotic therapy as it provides
results rapidly without the need for expensive techniques,
such as those based on PCR, that have a similar response
time [21]. Besides the initial cost, if this methodology is
appropriately transferred to a routine basis MALDI-TOF is a
simple and low-demand method, which is an additional
advantage. MALDI-TOF mass spectrometry could also be
used to detect other types of antibiotic resistance mecha-
nisms in bacteria, which involve a change in the antibiotic
used, not prescribed, as not always the antibiotic prescribed is
a good marker for detecting an speciﬁc resistance mechanism,
such as enzymatic modiﬁcation of aminoglycosides or chl-
oramphenicol [19].
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